Critical Care Therapeutics in Major Developed Markets New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market Expected To Grow At CAGR Of 7.5% Between Years 2013-2020


The Report Critical Care Therapeutics in Major Developed Markets to 2020 – New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 – New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates. The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings. The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 – RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) – are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

View Report At :http://www.marketresearchreports.biz/analysis/211679

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:

  • A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns

  • Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals

  • A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period

  • Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets

  • Key drivers and restraints that have had and are expected to have a significant impact on the market

  • An overview of major licensing and co-development agreements that could affect growth trends

Download Sample copy of this Report at :

http://www.marketresearchreports.biz/sample/sample/211679

Reasons to Buy

  • The report will enhance your decision-making capability by allowing you to:

  • Align your product portfolio to markets with high growth potential

  • Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth

  • Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market

  • Develop key strategic initiatives based on an understanding of key focus areas and leading companies

  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Albumin in Critical Care

2.1.1 Overview

2.1.2 Diseases or Conditions Indicated for Albumin

2.1.3 Epidemiology

2.1.4 Other Treatment Options

2.1.5 Treatment Patterns

2.2 Anti-Thrombin III Concentrates in Critical Care

2.2.1 Overview

2.2.2 Anti-Thrombin Deficiencies

2.2.3 Epidemiology

2.2.4 Treatment Options

2.2.5 Treatment Patterns

2.3 Factor XIII Concentrates in Critical Care

2.3.1 Overview

2.3.2 FXIII Deficiencies

2.3.3 Epidemiology

2.3.4 Treatment Options

2.3.5 Treatment Patterns

2.4 Fibrinogen Concentrates in Critical Care

2.4.1 Overview

2.4.2 Fibrinogen Deficiencies

2.4.3 Epidemiology

2.4.4 Treatment Options

2.4.5 Treatment Patterns

2.5 Prothrombin Complex Concentrate in Critical Care

2.5.1 Overview

2.5.2 Diseases or Conditions Indicated for Prothrombin Complex Concentrate

2.5.3 Epidemiology

2.5.4 Treatment Options

2.5.5 Treatment Patterns

3 Therapeutic Landscape

3.1 Albumin Products

3.1.1 Buminate (albumin, human) – Baxter

3.1.2 Zenalb (human albumin) – Bio Products Laboratory

3.1.3 Human Albumin Biotest (albumin, human) – Biotest

3.1.4 AlbuRx (albumin) – CSL Behring

3.1.5 Albuminar (albumin, human) 5% – CSL Behring

3.1.6 Albutein (albumin (human)) – Grifols

3.1.7 Albuked (human albumin) – Kedrion

3.1.8 Vialebex (human albumin) – French Fractionation and Biotechnology Laboratory

3.1.9 Albunorm (human albumin) – Octapharma

3.1.10 Alburaas (human albumin) – Shanghai RAAS

3.2 Anti-Thrombin Concentrates

3.2.1 Atryn (antithrombin alfa) – rEVO Biologics

3.2.2 Thrombate III (AT III human) – Grifols

3.2.3 Anbinex (AT III human) – Grifols

3.2.4 Kybernin P (AT III human) – CSL Behring

3.2.5 Aclotine (AT III, human) – French Fractionation and Biotechnology Laboratory

3.2.6 Anti-Thrombin III (AT III human) – Baxter

3.2.7 AT III Kedrion (AT III human) – Kedrion

3.2.8 Neuart (AT III, human) – Mitsubishi Tanabe

3.3 Factor XIII Concentrates

3.3.1 Fibrogammin/Corifact (factor XIII) – CSL Behring

3.3.2 NovoThirteen/Tretten (catridecacog) – Novo Nordisk

3.4 Fibrinogen Concentrates

3.4.1 Haemocomplettan P/Riastap (fibrinogen concentrate, human) – CSL Behring

3.4.2 Clottafact/Clottagen (fibrinogen concentrate, human) – French Fractionation and Biotechnology Laboratory

3.4.3 Other Marketed Fibrinogen Concentrates

3.5 Prothrombin Complex Concentrates

3.5.1 Beriplex P/N/Confidex/Kcentra (Prothrombin Complex Concentrate [Human]) – CSL Behring

3.5.2 Bebulin VH (factor IX complex, vapor heated) – Baxter

3.5.3 Cofact (prothrombin complex concentrate) – Sanquin

3.5.4 Octaplex 500 (human prothrombin complex) – Octapharma

3.5.5 Profilnine SD – Grifols

3.5.6 Uman Complex DI – Kedrion

4 Pipeline for Critical Care Market

4.1 Overview of Pipeline

4.2 Promising Pipeline Candidates

4.2.1 Octaplex 500 (human prothrombin complex) – Octapharma

4.2.2 KW-3357– Kyowa Hakko Kirin

4.2.3 Human AT Concentrate – Grifols

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

banner ";